PMID- 37197506
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230519
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 15
IP  - 4
DP  - 2023 Apr 28
TI  - Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in 
      advanced non-small cell lung cancer: a retrospective cohort study.
PG  - 2003-2011
LID - 10.21037/jtd-23-289 [doi]
AB  - BACKGROUND: Programmed cell death 1 (PD-1) inhibitors are beneficial for patients 
      with advanced lung cancer. However, the population who will benefit from PD-1 
      inhibitors is limited, and their efficacy needs to be further improved. 
      Antiangiogenic agents may regulate tumor microenvironment to improve 
      immunotherapy efficacy. This real-world study sought to investigate the efficacy 
      and safety of anlotinib combined with PD-1 inhibitors in the treatment of 
      advanced non-small cell lung cancer (NSCLC). METHODS: In total, 42 advanced NSCLC 
      patients were included in this retrospective study. All the patients received 
      anlotinib combined with PD-1 inhibitors from May 2020 to November 2022. The 
      progression-free survival (PFS), objective response rate (ORR), disease control 
      rate (DCR), and adverse events (AEs) of the patients were evaluated. RESULTS: The 
      patients had an overall median PFS of 5.721 months [95% confidence interval (CI): 
      1.365-10.076]. The median PFS and ORRs of the male patients compared to the 
      female patients were 10.553 vs. 4.340 months, and 36.4% vs. 0.0%, respectively 
      (P=0.010 and 0.041). The DCRs for the first-, second-, and third-line therapies 
      were 100%, 83.3%, and 64.3%, respectively (P=0.096). In relation to the 
      pathological types, the ORRs of the sarcoma, squamous, and adenocarcinoma 
      patients were 100.0%, 33.3%, and 18.5%, respectively (P=0.025). The DCRs of 
      patients with the tumor protein 53 (TP53) mutation, other status, and epidermal 
      growth factor receptor (EGFR) mutations were 100.0%, 81.5%, and 40.0%, 
      respectively (P=0.020). All-grade AEs occurred in 52.38% of the patients. The 
      grade 3 AEs were hypertension (7.14%), pneumonia (2.38%), and oral mucositis 
      (2.38%). In total, 3 patients discontinued treatment due to anemia, oral 
      mucositis, and pneumonia, respectively. CONCLUSIONS: Anlotinib combined with PD-1 
      inhibitors has potentially good efficacy and a tolerated safety profile in the 
      treatment of advanced NSCLC patients.
CI  - 2023 Journal of Thoracic Disease. All rights reserved.
FAU - Ye, Xuanting
AU  - Ye X
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Huang, Aimi
AU  - Huang A
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Zhou, Yan
AU  - Zhou Y
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Kuang, Yanbin
AU  - Kuang Y
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Wang, Weimin
AU  - Wang W
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Gu, Aiqin
AU  - Gu A
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Xu, Ling
AU  - Xu L
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230423
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC10183545
OTO - NOTNLM
OT  - Anlotinib
OT  - PD-1 inhibitors
OT  - advanced
OT  - non-small cell lung cancer (NSCLC)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jtd.amegroups.com/article/view/10.21037/jtd-23-289/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/05/18 01:07
MHDA- 2023/05/18 01:08
PMCR- 2023/04/28
CRDT- 2023/05/17 20:02
PHST- 2023/02/13 00:00 [received]
PHST- 2023/04/20 00:00 [accepted]
PHST- 2023/05/18 01:08 [medline]
PHST- 2023/05/18 01:07 [pubmed]
PHST- 2023/05/17 20:02 [entrez]
PHST- 2023/04/28 00:00 [pmc-release]
AID - jtd-15-04-2003 [pii]
AID - 10.21037/jtd-23-289 [doi]
PST - ppublish
SO  - J Thorac Dis. 2023 Apr 28;15(4):2003-2011. doi: 10.21037/jtd-23-289. Epub 2023 
      Apr 23.